Taken together, our data demonstrates that the combination of Myc-overexpressing tumor cell vaccine with check point inhibitors is an efficient and relatively safe therapeutic strategy for treating neuroblastoma in a mouse model. This evidence concerns the gene MYC and neuroblastoma.